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Highlights  
 The earlier developed gentamicin model for adult critically ill patients is valid for use in the 
AMC ICU population but not in the CHU Nîmes ICU population. This may have been caused 
by other gentamicin pharmacokinetics as other population PK parameters estimates were 
found.   
 Prior validation of population PK models with data from the population for which the model 
is intended to be used is recommended.   
 The earlier identified association between low albumin concentrations and an increased 
central volume of distribution of gentamicin in ICU patients was confirmed. This association 
implies that hypoalbuminaemia may result in a Cmax below the targeted range (<15 mg/L). 
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Abstract 
Before population pharmacokinetic (PK) models can be clinically applied to aid in dose 
selection of antibiotics, external validation of the model is warranted. The aim of this study 
was to assess the predictive performance of a gentamicin population PK model in intensive 
care unit (ICU) patients in two independent populations of Western critically ill patients.  
 
Methods  
Data from the same ICU as used for the earlier model development (Academic Medical 
Centre, Amsterdam (AMC)) and from the Centre Hospitalier Universitaire de Nîmes (CHU 
Nîmes) were collected. Primary endpoints were bias and accuracy. The model was regarded 
as valid if bias was not significantly different from 0 and accuracy was equal to or less than 
2.5 mg/L. Nonlinear mixed-effects modelling (NONMEM) was used for data analysis. 
 
Results 
The AMC validation dataset consisted of 192 samples from 66 ICU patients and the CHU 
Nîmes dataset of 230 gentamicin samples from 50 ICU patients. The structural model could 
predict the gentamicin plasma concentrations in the AMC population with a non-significant 
bias (0.35, 95%CI: -0.11–0.81) and a sufficient accuracy of 2.5 mg/L (95%CI: 2.3–2.8). The 
gentamicin plasma concentrations were overpredicted in the CHU Nîmes population with a 
significant bias of 4.8 mg/L (95%CI: 4.00–5.62) and an accuracy of 5.5 mg/L (95%CI: 4.7–
6.2).  
 
Conclusion  
The model is valid for use in the AMC ICU population but not in the CHU Nîmes ICU 
population. This illustrates that caution is needed when using a population pharmacokinetic 
model in an external population.  
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1.  Introduction  
Aminoglycosides and especially gentamicin is often included in empirical broad-spectrum 
antibiotic therapy for treatment of severe sepsis. Indeed, as administering the right dose of 
the right drug as soon as possible to a septic patient has been shown to decrease the 
mortality rate.[1–3] In case of gentamicin, the dose is considered appropriate when a 
maximum gentamicin plasma concentration (Cmax) / minimum inhibitory concentration (MIC) 
ratio of 8-10 is classically targeted leading to faster clinical response and an increased 
probability of cure.[4–6] According to Dutch therapeutic drug monitoring (TDM) guidelines, a 
gentamicin Cmax of 15-20 mg/L is considered therapeutic whereas French gentamicin 
dosing guidelines recommend targeting 30-40 mg/L.[7–9] Interindividual variability (IIV) in 
gentamicin pharmacokinetics in ICU patients is however large, making the probability that a 
Cmax/MIC≥8-10 is reached with a starting dose of 5 mg/kg only 27% for organisms with a 
MIC of 1 mg/L.[10,11] 
Population pharmacokinetic (PK) models can help to understand the complex 
pharmacokinetics in critically ill patients and identify covariates that explain part of the IIV. 
Such models can aid in selecting the right starting dose and optimizing individual dosing 
regimens. Previously, Hodiamont et al. developed a population PK model for gentamicin in 
ICU patients.[12] Plasma albumin concentrations were identified as a significant covariate on 
the central volume of distribution. Continuous venovenous hemofiltration (CVVH) and 
creatinine clearance calculated based on a 6 hour urine portion (CalcCLcr), as a measure of 
renal function were identified as covariates on clearance.[12] External validation of this 
model is necessary to confirm whether this model can reliably be used for calculation of the 
appropriate gentamicin (starting) doses. The aim of this study was to externally validate the 
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previously developed population PK model by evaluating its predictive performance in 
cohorts from two different ICUs. A second objective of the study was to validate the effect of 
albumin on volume of distribution of gentamicin in ICU patients to ascertain that this 
covariate could aid in selecting the initial dose.  
2. Materials and methods  
2.1 Patients and data  
Datasets from two ICU populations were used for the external validation of the population PK 
model. For the first cohort, data were collected at the same department as the model was 
build, namely the ICU of the Academic Medical Centre (AMC) Amsterdam, The Netherlands. 
Data were collected between November 7, 2016 and March 15, 2017 in a prospective 
observational design. All adult (≥18 years) patients admitted to the ICU receiving gentamicin 
were included, if at least one gentamicin concentration measurement was available. 
Pregnant patients and patients on hemodialysis were excluded. The AMC institutional review 
board reviewed the study and gave a waiver for informed consent, as therapeutic drug 
monitoring (TDM) is routinely conducted at the ICU of the AMC and only anonymous data 
obtained during routine clinical care were used in this study.    
The patients received a gentamicin starting dose of 5 mg/kg total body weight if sepsis of 
unknown origin was suspected or 3 mg/kg total body weight as part of endocarditis 
treatment. Part of the samples for the dataset originated from therapeutic drug monitoring 
(TDM), which is routinely conducted at the ICU of the AMC. To verify whether the Cmax was 
therapeutic (15-20 mg/L) a sample is drawn 30 minutes after ending the first gentamicin 
administration, which was infused over 0.5h. A follow-up blood sample was drawn the next 
morning around 6 a.m., which was used to estimate when the gentamicin concentration 
drops below 1 mg/L and thus when a next dose can be administered. At least three times a 
week follow-up samples are collected to check whether the dosing interval is still appropriate. 
Additionally, collected samples consisted of waste material from blood gas samples drawn 
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from the ICU patients treated with gentamicin, assuring random sampling. The samples were 
stored at room temperature for a maximum of 96 hours and centrifuged at 2750G for 5 
minutes to separate the blood plasma, which was stored in the -80 °C freezer and analyzed 
within 100 days.[13] Time points of gentamicin administration and of blood sample collection 
were witnessed during the day where possible and otherwise collected as registered in the 
electronic patient data information system of the hospital. Moreover, the duration of infusion 
was witnessed, as this duration often differs from the 30 minutes infusion prescribed in the 
protocol. 
Gentamicin plasma concentrations were measured with a Fluorescence Polarization 
Immunoassay (Cobas Integra 400+ autoanalyzer). The Cobas has a lower limit of 
quantification (LLOQ) of 0.5 mg/L and the accuracy was 96.1%, 104.0% and 103.1% at 
concentrations of 2.16, 4.86 and 7.88 mg/L respectively. 
The following patient characteristics were collected from the electronic patient data 
information system of the hospital: age, gender, total body weight (TBW), length, creatinine 
level, albumin serum concentration, total daily diuresis (TDIU), application of CVVH and the 
severity of disease described by the sequential organ failure assessment (SOFA) score. 
TDIU data were collected as measure for renal function as unfortunately data on CalcCLcr
 
levels were not available and TDIU was found to be the second best parameter predicting 
the gentamicin clearance in the previously developed model.[12] An albumin level was 
denoted as missing when no albumin level was known 24 hours before or after a gentamicin 
infusion or a gentamicin sample collection whereas all other parameters, such as SOFA 
score and TDIU were denoted as missing when no value was recorded 12 hours before or 
after a gentamicin infusion or a gentamicin sample collection. The ideal body weight (IBW) 
was calculated according to equation 1 and 2. The dataset thus created is referred to as the 
AMC data. 
IBWmen (kg) = 50 + 0.91 x (length(cm) – 152)   (1) 
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IBWwoman (kg) = 45 + 0.91 x (length(cm) – 152)    (2) 
The second dataset came from the Centre Hospitalier Universitaire (CHU) in Nîmes, 
France.[7,14] As this is an observational study, the Institutional Review Board approved the 
study and waived the need for consent. These data were collected in ICU patients (≥18 
years) that received gentamicin in one of the following two periods: June 2 until November 
29, 2013 or October 30, 2014 until March 10, 2015. The data from the two periods were 
combined into one dataset as there were only statistically significant differences (p-value 
<0.05) between both periods in age and SOFA score, which were not identified as significant 
covariates in the previously developed model, thus no influence on the predictive 
performance was expected. In the first inclusion period patients received a starting dose of 
≥3 mg/kg gentamicin based on their total bodyweight at admission. During the second period 
gentamicin 8 mg/kg body weight was administrated as starting dose. During both periods 
gentamicin was administrated in a 30-minute intravenous infusion and Cmax, 30 minutes 
after the end of infusion, and trough levels were routinely collected and measured with an 
automated Immunoassay with a Cobas C system. The LLOQ was 0.4 mg/L and three levels 
of quality controls were performed daily (1.7, 4.5 and 6.8 mg/L). Information for the purpose 
of this study on albumin concentrations, application of CVVH, creatinine concentrations, 
TDIU, SOFA score, weight, height, age and gender were retrospectively collected from the 
electronic patient files. IBW was calculated following equation 1 and 2. Missing data was 
handled the same way as in the AMC dataset. This dataset is referred to as the CHU Nîmes 
data. 
2.2 Data analysis  
With the use of the two datasets the previously developed population PK model for 
gentamicin ([12]) was validated using Bayesian estimation in NONMEM (v7.3.0, Icon 
Development Solutions, Ellicott City, USA).[15] The population PK parameters were fixed to 
the final estimates of the previously developed model and maximum evaluations (MAXEVAL) 
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was set to 0. The predictive performance of this model without covariates, referred to as the 
structural model, as well as the predictive performance of the model with the covariates, 
referred to as the final model, was examined.  
The structural population PK model is a two-compartment model with allometrically scaled 
PK parameters to an IBW of 70 kg. Furthermore, a clearance parameter was separately 
estimated for patients on and off CVVH. IIV was estimated on the central volume of 
distribution and on both clearance parameters, using a log-normal distribution. Interoccasion 
variability (IOV) was estimated on the clearance parameter off CVVH. The final model 
included a negative association between albumin level and the central volume of distribution 
and a positive correlation between TDIU and clearance off CVVH. The model including TDIU 
as covariate on clearance off CVVH was used as CalcCLcr data were not available. Details 
on the structural and final model can be found in reference 12. 
The predictive performance of the model was evaluated by comparing the population 
predicted concentrations (Cpred) with the observed concentrations in the datasets (Cobs). 
Primary endpoints for the predictive performance were the mean error (ME, equation 3) and 
mean absolute error (MAE, equation 4) calculated as measurements for bias and 
accuracy.[16,17] 
   
 
 
∑                      (3) 
    
 
 
∑                    (4) 
Where n represents the number of observations of all individuals. If 0 was included in the 
95% confidence interval (CI) of ME, no significant bias was present. When this was the case 
and a MAE of ≤2.5 mg/L was obtained, the model was regarded as valid. The MAE cut-off of 
2.5 mg/L was chosen because a deviation of 2.5 mg/L from 17.5 mg/L, the middle of the 
therapeutic window of Cmax (15-20 mg/L), still results in a therapeutic Cmax and as such in 
a smaller than 50% chance of a false positive indication for dose adjustment. To visualize the 
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predictive performance Bland-Altman plots and Visual Predictive Checks (VPCs) were 
created.[18] PsN (v3.5.3, Uppsala University, Sweden) was used for the creation of 
VPCs.[19] Pirana (v2.9.4., Software &Consulting BV, The Netherlands) was used for model 
management. 
Furthermore, an analysis was performed to compare the PK of gentamicin from the present 
validation study with the PK of gentamicin in the ICU population in which the model was 
developed. Both validation datasets were fitted (MAXEVAL>0) to the structural model using 
the first order conditional estimation method with interaction in NONMEM (FOCE+I). The 
final population parameter estimates from the previously developed model served as initial 
estimates. The newly estimated pharmacokinetic parameters of the two validation data sets 
were compared with the parameter estimates of the previously developed structural model 
and their 95%CI.  
For the secondary objective of this study, the data from the cohorts were fitted to the 
previously developed final model with and without albumin as a covariate on central volume 
of distribution (V1), using FOCE+I. A correction for missing albumin values was applied, as 
described earlier.[20] When the objective function value (OFV), calculated based on the 
likelihood ratio test, increased with 3.84 units or more [15] for the final model without albumin 
relative to the final model with albumin, albumin was regarded as having a statistically 
significant association with V1 (p<0.05 based on a χ2 –distribution with 1 degree of freedom). 
Furthermore, an increase in the estimate of IIV in V1 was taken into account as an indication 
that less IIV was explained without this covariate. When albumin was found to be of 
significant influence on V1, Cmax and V1 after the first dose (Cmax after subsequent doses 
are affected by TDM) were plotted against albumin to visualize this association. The Cmax 
was calculated as the individual prediction of the gentamicin concentration at 0.5 hours after 
end of gentamicin administration.   
2.3 Statistics  
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Statistical tests were performed using SPSS Statistics (v23, IBM, USA). Continuous 
variables were tested with the unpaired T-test if normally distributed. The Mann Whitney U 
test was executed when continuous variables were non-normally distributed. Categorical 
variables were analyzed using the Chi-square test. A p-value <0.05 was regarded as 
statistically significant. 
3. Results  
1. Data 
For the AMC dataset, 66 patients receiving a total of 122 gentamicin administrations were 
included. One patient was excluded because of the use of hemodialysis. A median of 1 dose 
was administered per patient with a range of 1 to 7. The AMC data consisted of 192 
gentamicin concentration-time samples. Of these, 131 (68%) were routinely collected 
samples during TDM and 61 (32%) were collected from waste material blood samples. On 
average 2.9 samples were measured per patient, with a median of 1 sample per dose 
interval (range 1 to 8). The number of concentrations below the limit of quantification (BLQ: 
<0.5 mg/L) was 15, i.e. 7.8% of all samples, and these were excluded.  Fifty-six patients 
received gentamicin for the treatment of sepsis and 8 for endocarditis. Two patients were 
treated with gentamicin because of a pneumonia (risk) after the submersion or aspiration of 
freshwater. The parameters IBW, CVVH, albumin and TDIU that were used in the previously 
developed model, were available in respectively 80%, 100%, 79% and 100%.  
The CHU Nîmes data consisted of 50 patients that received a total of 149 gentamicin 
administrations (median 3 doses/patient; range 1-6). This dataset consisted of 230 
gentamicin concentration-time samples. The number of samples ranged from 1 to 11 per 
patient (median 5), with a median of 2 samples per dose interval (range 1 to 5). Of these 
concentrations, 26 (11.3%) were BLQ (<0.4 mg/L) and were excluded. The covariates IBW, 
CVVH, albumin and TDIU that were used in the final model, were available in respectively 
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100%, 100%, 29% and 86%. In Table 1 the patient baseline characteristics from the AMC 
data and the CHU data are presented.  
3.2 Predictive performance  
Table 2 presents the ME (bias) and the MAE (accuracy) for the structural and the final model 
of the AMC data and the CHU data. The validation of the structural model using the AMC 
data yielded a statistically non-significant bias of 0.35 mg/L (95% CI: -0.11 – 0.81). The MAE 
was 2.54 mg/L (95%CI: 2.26 – 2.82) and thus equaled the prior set cut-off. For the final 
model (addition of the covariates albumin and TDIU) a small significant bias of 0.81 mg/L 
was found but the accuracy remained the same.  
Validation of the structural model with the CHU data resulted in an upward bias of 4.81 mg/L, 
which was significantly different from 0 (95% CI: 4.00 – 5.62). Furthermore, accuracy was 
5.45 mg/L. The predictive performance of the final model was not better as it yielded a bias 
of 6.89 mg/L (95%CI: 5.92 – 7.81) and an accuracy of 7.17 mg/L.  
The predictive performance is visualized in the Bland-Altman plots in Figure 1. These plots, 
as well as the VPCs in figure 2, indicate that the model can estimate the gentamicin 
concentrations without bias and reasonable accuracy in the AMC population, but that the 
concentrations are overpredicted in the CHU population. The VPC also shows that in both 
populations the models overestimate the IIV. However, this overestimation is larger in the 
CHU population.  
The results of the comparison of the PK of gentamicin from the present validation cohorts 
with the PK of gentamicin in the ICU population in which the model was developed are 
presented in Table 3. Mean CL (both off and on CVVH) and the mean central volume of 
distribution (V1) as estimated with the CHU data were higher and outside the 95%CI of the 
corresponding parameter estimates from the previously developed model. This is consistent 
with the overprediction seen when validating the model with the CHU data.  
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3.3 Influence of serum albumin concentration 
When the AMC data were fitted to the final model, the OFV was 7.782 units higher in the 
model without albumin concentration as a covariate on V1 (p<0.01). Furthermore, an 
increase in the estimate of the IIV in V1 from 32.4% to 36.3% was observed. The association 
between albumin concentration and V1 as well as the resulting effect on the Cmax is shown 
in Figure 3. This figure shows that serum albumin concentrations <20 g/L are associated with 
a low and often subtherapeutic Cmax. The association between albumin concentration and 
V1 was not tried to be validated with the CHU data as 71% of the albumin data was missing.    
4. Discussion  
The predictive performance of a previously developed population PK model of gentamicin in 
ICU patients was tested in two different populations of ICU patients. The prospectively 
collected AMC data could be sufficiently predicted by the structural model, as shown by a ME 
that was not statistically significantly different from 0 and a MAE of 2.5 mg/L. However, an 
overprediction was observed when predicting the concentrations of the CHU data set. In 
addition, the negative association between gentamicin central volume of distribution and 
albumin level that was identified during development of the previously developed model 
could be confirmed with the collected AMC data. 
A strength of this validation study was the fact that two independently collected datasets from 
different countries including patients with a different casemix were used. These datasets 
were selected with the assumption that these would be representative for the Western ICU 
population. A valid model would have been capable of predicting both the AMC and the CHU 
Nîmes data appropriately.    
A limitation of this study was the fact that creatinine clearance data, calculated based on a 6-
hour urine portion (CalcCLcr) which was identified as best measure for kidney function to 
predict gentamicin CL off CVVH in the previously developed model, was not available for 
both validation cohorts and could therefore not be used. Instead, TDIU was used as measure 
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for renal function, as this covariate had the second best association, and these covariate 
data was available. However, TDIU is likely to reflect the renal function less reliably, as the 
use of diuretics was not accounted for. This could explain why ME and MAE were not better 
when the concentrations were calculated with the final model instead of the structural model 
(Table 2). Another limitation was that the CHU data had a low percentage of available 
albumin levels (29%), making this dataset unsuitable for the verification of the association 
between V1 and albumin level. The reason why albumin level was not often available in the 
CHU data is that this covariate is not measured frequently on a routine basis and because 
this covariate was not captured in the context of the study during which the CHU database 
was built. 
Whether the observed bias and accuracy as obtained with the CHU Nîmes data can be 
regarded as high or low is difficult to assess as no previous studies that externally validated a 
population PK model for gentamicin in critically ill patients could be identified. However the 
bias of 4.81 mg/L found when predicting the gentamicin concentrations of the CHU Nîmes 
cohort with the structural model indicates a statically significant overestimation, which causes 
a risk of unrightfully not increasing the dose. 
The statistically significant ME and large MAE observed with the CHU Nîmes data may be 
caused by the fact that this ICU population was too different from the AMC ICU population. 
This is illustrated in Table 1 where the ICU patients in the CHU data set have lower SOFA-
scores, lower mortality rates and lower serum creatinine levels, which indicates a less ill 
population. However, this only seems to be  part of the explanation as the expectation would 
then be that the CHU cohort would have a lower total, central plus peripheral, volume of 
distribution than the more severely ill AMC population instead of the higher volume of 
distribution that was found (Table 3).  
In theory it could be true that the found high volume of distribution in the French population 
could be explained by low albumin values which were missing (negative association). 
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However, the limited albumin samples that are available in the CHU population(29%) are in 
the same range or higher as the model building population and the newly prospectively 
collected AMC population (table 1 in the revised manuscript) . In addition, higher albumin 
levels are expected in this less ill population. Therefore, we are convinced that the missing 
albumin values are unlikely to be responsible for the differences between the volumes of 
distribution between the two ICU populations investigated.  
So another part of the explanation might be that the PK of gentamicin in the CHU Nîmes ICU 
population is indeed different from the AMC ICU population. Also in comparison with 
literature, a high V1 was found in the CHU Nîmes population [10,21,22]. In addition, 
gentamicin CL off CVVH in the AMC population seems relatively low in comparison with the 
CHU Nîmes population (Table 3) and with literature [10,21]. 
The results of this validation study show in a more general sense that the previously 
developed model cannot simply be used for other ICU populations. This underscores the 
importance of external model validation, as a seemingly good model may not perform 
adequately in other institutions, especially if the model did not originate from a sufficiently 
heterogeneous population. Prior validation of the model is recommended with data from the 
population in which the model is intended to be used.  
Furthermore, addition of serum albumin concentrations as a covariate significantly improved 
the fit of the model when using the AMC data and the previously identified association 
between the central volume of distribution of gentamicin and albumin concentration could 
thus be confirmed.[12] The previous study showed that especially patients with very low 
albumin concentrations of <15 g/L are prone to developing sub therapeutic Cmax values.[12] 
Although these very low Cmax values were barely observed in our study population, an 
association was confirmed. As such, taking the albumin level of an ICU-patient into account 
may improve gentamicin dosing, e.g. by measuring the Cmax early in the course of treatment 
in ICU patients with serum albumin concentrations <20 g/L to ascertain Cmax target 
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exposure, or by prescribing at least 6 mg/kg in patients with albumin levels <20 g/L, 
especially when TDM of Cmax levels is not conducted. This recommendation is strengthened 
by the fact that previous studies also have observed a negative association between the 
volume of distribution of aminoglycosides and serum albumin concentrations.[12,23,24] 
5. Conclusion  
This external validation study shows that the previously developed structural population PK 
model for critically ill patients receiving gentamicin can predict gentamicin concentrations 
without bias and with acceptable accuracy in the ICU population admitted to the hospital 
where data for model development originated from. However the model overpredicts 
gentamicin concentrations in an ICU population from another Western hospital. Therefore, 
the model may not easily be used in other western ICU populations. In general, prior 
validation of population PK models with data from the population in which the model is 
intended to be used is recommended.   
In addition, the negative association between the central volume of distribution of gentamicin 
and albumin concentrations in ICU patients was confirmed. This association implies that 
hypoalbuminaemia may result in a Cmax below the targeted range. 
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Figure 1: Bland Altman plots of the predictive performance of the previously developed model based 
on (A) the AMC data predicted by the structural model, (B) the AMC data predicted by the final model, 
(C) the CHU data predicted by the structural model and (D) the CHU data predicted by the final model. 
The differences between the population predicted and measured concentrations are plotted against 
the measured gentamicin concentration. The dotted lines represents the ±1.96 standard deviation and 
the solid line the mean error.  
 
Figure 2: Prediction corrected visual predictive checks of the validation of the original model with (a) 
the data from the AMC ICU population using the structural model, (b) the data from the AMC ICU 
population using the final model, (c) the data from the CHU ICU population using the structural model 
and (d) the data from the CHU ICU population using the final model. The solid and dotted red lines 
show respectively the median, 5 and 95 percentiles of the measured concentrations. The red box 
indicates the 95%CI of the median of the predicted concentrations and the blue boxes the 95% CI of 
the 5 and 95 percentiles of the predicted concentrations. A model shows adequate predictive 
performance when the solid and dotted lines in the VPC run through the red and blue boxes 
respectively. IIV is overestimated when less than 5% of the concentration points are outside the blue 
boxes on both sides. 
 
Figure 3: Albumin concentration in relation to (a) the estimated central volume of distribution (V1) of 
gentamicin and the (b) estimated peak concentration (Cmax) at 0.5 h after the end of gentamicin 
administration, after fitting the AMC data to the final model. Only the Cmax and V1 of the first 
administration are shown. The dotted lines represent the therapeutic window for Cmax of 15 to 20 
mg/l.   
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Table 1: Patient characteristics at baseline  
 
 
 
Validation cohorts  
  
 
Original model 
(n=44) [12] 
AMC Amsterdam 
(n=66) 
CHU Nîmes 
(n=50) 
P-value* 
Female [n (%)] 24 (55) 13 (20) 21 (42) 0.091 
Age (years) 61 (50-68) 64 (55-73) 62 (49-75) 0.614 
Mean dose (mg/kg body weight)  4 (3.8-4.5) 4.8 (4.7-5.1) 6.3 (5.2-7.5) <0.001 
Total body weight (kg) 70.5 (60-85.8) 77.6 (67.4-89.5) 72.0 (59.1-87.5) 0.198 
Ideal body weight (kg) 68.2 (63.6-70.6) 69.1 (60.5-74.6) 62.3 (57.0-66.4) 0.001 
Height (cm) 170 (165-175) 174 (168-180) 168 (161-170) 0.01 
SOFA score - 9 (6-11) 5.5 (3-9) <0.001 
APACHE II score 17 (12-23) - - - 
CVVH [n (%)] 5 (11.4) 9 (14) 1 (2) 0.027 
Serum creatinine (µmol/L) 115 (89.3-179) 112.5 (77.8-181.8) 87 (57-114.5) 0.02 
Total daily diuresis (ml)  785 (350-1690) 1125 (503 -2128) 1422 (721 -2150) 0.22 
Albumin (g/L) 21.5(19-25.3) 25 (19-31) 28.7 (25.1-32.8) 0.002 
Death during ICU admission [n (%)] - 12 (18) 4 (8)  0.098 
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Values are expressed as median (interquartile range), unless stated otherwise.  SOFA: Sequential Organ Failure 
Assessment, APACHE: Acute Physiology and Chronic Health Evaluation, CVVH: continuous venovenous hemofiltration 
*The p-values represent if there was a statistical difference between the two validation cohorts. 
 
 
Table 2: Predictive performance of the model using population predictions  
 AMC Amsterdam (n=66) CHU Nîmes (n=50) 
 Structural model Final model Structural model Final model 
Mean Error (mg/L) 0.35 (-0.11 – 0.81)  0.81 (0.33 – 1.30) 4.81 (4.00-5.62) 6.89 (5.92 – 7.81) 
Mean Absolute Error  
(mg/L)  
2.54 (2.26 – 2.82) 2.54 (2.21 – 2.86) 5.45 (4.72-6.17) 7.17 (6.27 – 8.07) 
Values are expressed as mean (95% confidence interval)  
 
Table 3: Pharmacokinetic parameter estimates of the prospective AMC ICU and CHU ICU 
population when the collected data are fitted with the previously developed structural model. 
   
Validation 
 
Structural Model [12] AMC Amsterdam CHU Nimes 
Parameter Estimate 95% CI Estimate 95% CI Estimate 95% CI 
CL not on CVVH 
(L/h/70 kg) 
1.92 1.47 – 2.37 2.39 1.933 – 2.85 3.93 2.99 – 4.87 
CL on CVVH 
(L/h/70 kg) 
2.08 1.79 – 2.37 1.60 1.22 – 1.97 2.46 2.37 – 2.55 
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V1 (L/70 kg) 21.2 19.39  – 23.01 23.9 21.20 – 26.61 28 24.90 – 31.10 
Q (L/h/70 kg) 2.26 1.58 – 2.94 0.625 0.17 – 1.08 1.68 0.02 – 3.34 
V2 (L/70 kg) 18.9 16.12 – 21.68 6.47 3.02 – 9.92 12.8 7.06 – 18.54 
 
Estimates are expressed as means. CI: Confidence interval, CL: clearance, CVVH: continuous venovenous hemofiltration, 
V1: central volume of distribution, Q; intercompartment clearance, V2: peripheral volume of distribution.  
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